BACKGROUND: HuR is an mRNA stability factor that binds to the AU-rich element-containing 3' untranslated region of the transcript. HuR overexpression is associated with increased tumor growth. Increased cytoplasmic HuR expression occurs in several cancer types, including colorectal cancer where it may contribute to the increased cyclooxygenase-2 (COX- 2) expression observed during tumorigenesis. To investigate expression of HuR in the colorectal adenoma-carcinoma sequence, we examined expression of HuR in colorectal mucosa of patients with familial adenomatous polyposis (FAP) and sporadic colorectal cancer with correlation to COX-2 expression. RESULTS: Cytoplasmic HuR staining was found in the epithelium of 10% of normal mucosa, 14.3% of adenomas and 88.9% of adenocarcinomas from FAP patients (p < 0.01) and in 68.8% of sporadic colorectal carcinomas. High epithelial COX-2 immunostaining was observed in 10% of normal, 8% of adenomas and all adenocarcinomas from FAP patients (p < 0.01) and in 69.5% of sporadic colorectal carcinomas. Positive cytoplasmic HuR immunostaining correlated with high COX-2 immunoreactivity in colon mucosa of FAP patients (p < 0.01) and in sporadic colorectal carcinomas. (p = 0.016) MATERIALS AND METHODS: HuR and COX-2 protein expression were studied by immunohistochemistry of normal colon mucosa (N=20), adenomas (N=112), carcinomas (N=9) from patients with FAP, and 141 sporadic colorectal adenocarcinomas (Dukes B and C). CONCLUSIONS: HuR is increasingly expressed in the cytoplasmic epithelial compartment in consecutive stages of the adenoma-carcinoma sequence in FAP. Also, COX-2 levels correlate with cytoplasmic expression of HuR in colonic epithelium of FAP patients and in sporadic colorectal cancer specimens. The role of cytoplasmic expression of HuR as a biomarker for progression of adenomas in FAP needs further study.
BACKGROUND:HuR is an mRNA stability factor that binds to the AU-rich element-containing 3' untranslated region of the transcript. HuR overexpression is associated with increased tumor growth. Increased cytoplasmic HuR expression occurs in several cancer types, including colorectal cancer where it may contribute to the increased cyclooxygenase-2 (COX- 2) expression observed during tumorigenesis. To investigate expression of HuR in the colorectal adenoma-carcinoma sequence, we examined expression of HuR in colorectal mucosa of patients with familial adenomatous polyposis (FAP) and sporadic colorectal cancer with correlation to COX-2 expression. RESULTS: Cytoplasmic HuR staining was found in the epithelium of 10% of normal mucosa, 14.3% of adenomas and 88.9% of adenocarcinomas from FAPpatients (p < 0.01) and in 68.8% of sporadic colorectal carcinomas. High epithelial COX-2 immunostaining was observed in 10% of normal, 8% of adenomas and all adenocarcinomas from FAPpatients (p < 0.01) and in 69.5% of sporadic colorectal carcinomas. Positive cytoplasmic HuR immunostaining correlated with high COX-2 immunoreactivity in colon mucosa of FAPpatients (p < 0.01) and in sporadic colorectal carcinomas. (p = 0.016) MATERIALS AND METHODS:HuR and COX-2 protein expression were studied by immunohistochemistry of normal colon mucosa (N=20), adenomas (N=112), carcinomas (N=9) from patients with FAP, and 141 sporadic colorectal adenocarcinomas (Dukes B and C). CONCLUSIONS:HuR is increasingly expressed in the cytoplasmic epithelial compartment in consecutive stages of the adenoma-carcinoma sequence in FAP. Also, COX-2 levels correlate with cytoplasmic expression of HuR in colonic epithelium of FAPpatients and in sporadic colorectal cancer specimens. The role of cytoplasmic expression of HuR as a biomarker for progression of adenomas in FAP needs further study.
Authors: Elizabeth Van Tubergen; Robert Vander Broek; Julia Lee; Gregory Wolf; Thomas Carey; Carol Bradford; Mark Prince; Keith L Kirkwood; Nisha J D'Silva Journal: Cancer Date: 2011-01-10 Impact factor: 6.860
Authors: Durga P Cherukuri; Tomo-O Ishikawa; Patrick Chun; Art Catapang; David Elashoff; Tristan R Grogan; James Bugni; Harvey R Herschman Journal: Mol Oncol Date: 2013-11-08 Impact factor: 6.603
Authors: Isabel López de Silanes; Myriam Gorospe; Hiroaki Taniguchi; Kotb Abdelmohsen; Subramanya Srikantan; Miguel Alaminos; María Berdasco; Rocío G Urdinguio; Mario F Fraga; Filipe V Jacinto; Manel Esteller Journal: Nucleic Acids Res Date: 2009-03-06 Impact factor: 16.971